Friday, November 1, 2013. On October 15, 2013, the International Journal of Clinical Practice reported the finding of Abdulmaged M. Traish, MBA, Ph.D. of Boston University School of Medicine and his associates of a beneficial effect for testosterone therapy in lowering metabolic syndrome and related cardiovascular disease risk in hypogonadal men.
The study included 255 men aged 33 to 69 years who had sought treatment for symptoms related to low testosterone and had low plasma total testosterone levels upon assessment. All men were treated with testosterone at the beginning of the study period, at six weeks, and every twelve weeks thereafter for up to five years. Weight, height and waist circumference were measured at these time points, and blood samples were assessed for lipids, fasting glucose, hemoglobin A1c, C-reactive protein (CRP, a marker of inflammation) and liver enzymes. All but eleven of the men included in the study had three or more metabolic syndrome components, which include increased waist circumference, hypertension, disordered lipids, and insulin resistance.
This is an excerpt from an article originally published in Life Extension Magazine.Simply click here to read the complete article.